The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm
Status:
Recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
This trial aimed to investigate the therapeutic efficacy of ruxolitinib in combination with
cytotoxic chemotherapy for post-myeloproliferative neoplasm secondary acute myeloid leukemia.